 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...213214215216217218219220221222223...235236» |
- Farydak (panobinostat) / Secura Bio
Enrollment change, Trial termination, Metastases: Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy (clinicaltrials.gov) - Sep 11, 2014
P1, N=7, Terminated, Sponsor: University of Southern California
N=50 --> 7 | Suspended --> Terminated; Adverse Events
- || gedatolisib (PF-05212384) / Celcuity
Trial primary completion date, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 10, 2014
P1/2, N=180, Recruiting, Sponsor: Pfizer
N=50 --> 7 | Suspended --> Terminated; Adverse Events Trial primary completion date: Sep 2016 --> Mar 2017
- | Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial, Metastases: Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Sep 9, 2014
P2, N=58, Not yet recruiting, Sponsor: University of Southern California
- || New P3 trial: COLOPEC: Adjuvant HIPEC in High Risk Colon Cancer (clinicaltrials.gov) - Sep 5, 2014
P3, N=176, Not yet recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- | napabucasin (BBI608) / Sumitomo Pharma
New P1 trial, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (clinicaltrials.gov) - Sep 5, 2014
P1, N=32, Recruiting, Sponsor: Boston Biomedical, Inc
- leucovorin calcium / Generic mfg.
Enrollment change: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Aug 29, 2014
P2, N=192, Recruiting, Sponsor: University of Arkansas
Trial primary completion date: Sep 2016 --> Mar 2017 N=144 --> 192
- | oxaliplatin / Generic mfg.
New P2 trial, Metastases: PUMCH-JZ: FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer (clinicaltrials.gov) - Aug 27, 2014
P2, N=75, Recruiting, Sponsor: Peking Union Medical College Hospital
- |||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, Metastases: Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR). (clinicaltrials.gov) - Aug 25, 2014
P2, N=80, Recruiting, Sponsor: Centre Oscar Lambret
N=144 --> 192 Not yet recruiting --> Recruiting
- ||| Elitek (rasburicase) / Sanofi, Rituxan (rituximab) / Roche
Metastases: Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma (clinicaltrials.gov) - Aug 22, 2014
P2, N=97, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 21, 2014
P3, N=242, Active, not recruiting, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting N=315 --> 242
- |||| Avastin (bevacizumab) / Roche
Biomarker, Enrollment open, Metastases: ASCENT: A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 21, 2014
P4, N=150, Recruiting, Sponsor: Hoffmann-La Roche
N=315 --> 242 Active, not recruiting --> Recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment closed, Trial primary completion date: Phase II Trial Evaluating OS With Therasphere (clinicaltrials.gov) - Aug 21, 2014
P2, N=58, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Mar 2015
- || telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 19, 2014
P1, N=124, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Mar 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- || New P2/3 trial: The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial (clinicaltrials.gov) - Aug 19, 2014
P2/3, N=262, Recruiting, Sponsor: Sun Yat-sen University
- Trial primary completion date, Metastases: Molecularly Tailored Therapy for Pancreas Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=20, Recruiting, Sponsor: Georgetown University
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Dec 2014 --> Jun 2015
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC (clinicaltrials.gov) - Aug 15, 2014
P3, N=390, Active, not recruiting, Sponsor: Alchemia Oncology
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Jan 2014 --> Sep 2014
- Enrollment change, Trial termination, Trial primary completion date: Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=6, Terminated, Sponsor: Southwestern Regional Medical Center
Trial primary completion date: Jan 2014 --> Sep 2014 N=25 --> 6 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jul 2014; Lack of enrollment
- DC-CIK / Hornetcorn Biotech
New P2 trial: Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=40, Not yet recruiting, Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
- | New P2 trial, Metastases: FORTUNE: Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=84, Recruiting, Sponsor: Sun Yat-sen University
- | Folotyn (pralatrexate) / Aurobindo
Enrollment open, Combination therapy: Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 15, 2014
P2, N=20, Recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
N=25 --> 6 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jul 2014; Lack of enrollment Not yet recruiting --> Recruiting
- ||| ipatasertib (RG7440) / Roche
Enrollment closed, Combination therapy, Metastases: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=122, Active, not recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | leucovorin calcium / Generic mfg.
Enrollment closed, Metastases: VELVET: OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=49, Active, not recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Avastin (bevacizumab) / Roche, GI-4000 / ImmunityBio
Enrollment closed, Metastases: A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI (clinicaltrials.gov) - Aug 15, 2014
P2, N=52, Active, not recruiting, Sponsor: Georgetown University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial initiation date: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - Aug 12, 2014
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: May 2013 --> Jun 2009
- ||||| onartuzumab (RG3638) / Roche
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Aug 12, 2014
P3, N=564, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: May 2013 --> Jun 2009 Recruiting --> Active, not recruiting | N=800 --> 564
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial initiation date, Metastases: FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer (clinicaltrials.gov) - Aug 11, 2014
P2, N=64, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=800 --> 564 Initiation date: Jan 2013 --> Sep 2013
- Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 8, 2014
P2, N=22, Active, not recruiting, Sponsor: University of Miami
Initiation date: Jan 2013 --> Sep 2013 Trial primary completion date: Apr 2014 --> Apr 2015
- |||| leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Trial primary completion date: AALL0232: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 8, 2014
P3, N=3154, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Apr 2014 --> Apr 2015 Trial primary completion date: Oct 2012 --> Jun 2014
- |||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial primary completion date, IO biomarker, Surgery: acns0333: Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov) - Aug 6, 2014
P3, N=70, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Oct 2012 --> Jun 2014 Trial primary completion date: Apr 2014 --> Apr 2015
- || Trial initiation date: AALL02P2: Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=168, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Apr 2014 --> Apr 2015 Initiation date: Sep 2008 --> Nov 2004
- ||| Avastin (bevacizumab) / Roche
Biomarker, Enrollment closed, Metastases: ASCENT: A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 5, 2014
P4, N=126, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Sep 2008 --> Nov 2004 Recruiting --> Active, not recruiting
- methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy (clinicaltrials.gov) - Aug 4, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Nov 2014
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment change: Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Aug 4, 2014
P2, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2014 --> Nov 2014 N=66 --> 33
- || Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial primary completion date: BOS2: Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (clinicaltrials.gov) - Aug 1, 2014
P2, N=360, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=66 --> 33 Trial primary completion date: Oct 2015 --> Oct 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 1, 2014
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: May 2013 --> Aug 2014
- || brivanib alaninate (BMS-582664) / ZAI Lab
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) (clinicaltrials.gov) - Aug 1, 2014
P1, N=72, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2013 --> Aug 2014 Initiation date: Feb 2009 --> Feb 2010 | Trial primary completion date: Jul 2012 --> Aug 2014
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment closed: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 1, 2014
P3, N=1900, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Feb 2009 --> Feb 2010 | Trial primary completion date: Jul 2012 --> Aug 2014 Recruiting --> Active, not recruiting
- Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 30, 2014
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Dec 2014
- | DC-CIK / Hornetcorn Biotech
New P2 trial, Surgery: Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer (clinicaltrials.gov) - Jul 30, 2014
P2, N=60, Active, not recruiting, Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
- |||| Erbitux (cetuximab) / Eli Lilly
Enrollment open, Trial initiation date, Trial primary completion date, Surgery, Metastases: ECKINOXE: Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer (clinicaltrials.gov) - Jul 30, 2014
P2, N=186, Recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Jun 2014 --> Dec 2014 Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> May 2012 | Trial primary completion date: Feb 2014 --> May 2012
- | Trial completion: Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jul 28, 2014
P2, N=36, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> May 2012 | Trial primary completion date: Feb 2014 --> May 2012 Active, not recruiting --> Completed
- |||| thioguanine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jul 27, 2014
P2, N=59, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Enrollment change, Trial termination, Trial primary completion date: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 24, 2014
P2, N=53, Terminated, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=180 --> 53 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2015
- Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer (clinicaltrials.gov) - Jul 24, 2014
P2, N=30, Recruiting, Sponsor: Bruckner Oncology
N=180 --> 53 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2015 Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> Jul 2014 | Trial primary completion date: Jul 2015 --> Jul 2016
- ||||||| doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma (clinicaltrials.gov) - Jul 24, 2014
P3, N=242, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> Jul 2014 | Trial primary completion date: Jul 2015 --> Jul 2016 Active, not recruiting --> Completed
- |||| thioguanine / Generic mfg.
Trial completion, Enrollment change: Combination Chemotherapy in Treating Children With Lymphoma (clinicaltrials.gov) - Jul 24, 2014
P2, N=221, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=90 --> 221
- | sapitinib (AZD8931) / AstraZeneca
Enrollment open, Trial initiation date, Combination therapy: PANTHER: Phase I/II Trial of Antagonism of HER in GI Cancer (clinicaltrials.gov) - Jul 23, 2014
P1/2, N=24, Recruiting, Sponsor: University College, London
Active, not recruiting --> Completed | N=90 --> 221 Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> May 2014
- |||| Stivarga (regorafenib) / Bayer
Trial completion, Combination therapy, Metastases: First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib (clinicaltrials.gov) - Jul 23, 2014
P2, N=54, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> May 2014 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date, Surgery, Metastases: Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 21, 2014
P2, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Trial primary completion date: Apr 2017 --> Oct 2017
- Avastin (bevacizumab) / Roche
Trial termination, Combination therapy, Metastases: High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 21, 2014
P2, N=10, Terminated, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Apr 2017 --> Oct 2017 Completed --> Terminated; Lack of funding